Ali KARADENİZ, Nejdet ŞİMŞEK, Serap YILDIRIM, Abdulkadir YILDIRIM, Akar KARAKOÇ, Yıldıray KALKAN

Effects of royal jelly on liver paraoxonase activity in rats treated with cisplatin

To evaluate the protective effects of royal jelly (RJ) on the changes caused by cisplatin in paraoxonase-1 (PON-1) and arylesterase (ARE) activities. Materials and methods: Twenty-four Sprague-Dawley rats were divided into 4 groups of 6: control, royal jelly (300 mg kg-1 day-1, cisplatin (7 mg kg-1 body weight), and royal jelly (300 mg kg-1 day-1 plus a single dose of cisplatin (7 mg kg-1 body weight). After the experimental procedures, blood and liver tissue samples were taken from each animal. The effects of RJ and cisplatin were evaluated by PON-1, ARE (in liver homogenates), and serum alanine aminotransferase measurements. The liver tissue was also histologically examined. Results: Administration of cisplatin reduced the PON-1 and ARE activities in the liver. However, in the rats given a pretreatment with RJ before the injection of cisplatin, the reduction caused by the cisplatin in the PON-1 and ARE activities was prevented at a significant level. These biochemical observations were supported by histological findings and suggested that RJ restored the cisplatin-induced structural alterations in the liver tissue by the way of its antioxidant, radical scavenging, and antiapoptotic effects. Conclusion: RJ may be a potential preventive agent against the hepatic toxicity associated with cisplatin therapy.

Anahtar Kelimeler:

Key words: Arylesterase, cisplatin, oxidative stress, paraoxonase, royal jelly

Effects of royal jelly on liver paraoxonase activity in rats treated with cisplatin

Keywords:

Key words: Arylesterase, cisplatin, oxidative stress, paraoxonase, royal jelly,

PDF

___

Guo H, Saiga A, Sato M, Miyazawa I, Shibata M, Takahata Y et al. Royal jelly supplementation improves lipoprotein metabolism in humans. J Nutr Sci Vitaminol (Tokyo) 2007; 53: 345-8.
Guo H, Ekusa A, Iwai K, Yonekura M, Takahata Y, Morimatsu F. Royal jelly peptides inhibit lipid peroxidation in vitro and in vivo. J Nutr Sci Vitaminol (Tokyo) 2008; 54: 191-5.
Şimşek N, Karadeniz A, Bayraktaroğlu AG. Eff ects of L-carnitine, royal jelly and pomegranate seed on peripheral blood cells in rats. Kafk as Univ Vet Fak Derg 2009; 15: 63-9.
Türk G, Ateşşahin A, Sönmez M, Ceribaşi AO, Yüce A. Improvement of cisplatin-induced injuries to sperm quality, the oxidant-antioxidant system, and the histologic structure of the rat testis by ellagic acid. Fertil Steril 2008; 89: 1474-81.
Gottfried M, Ramlau R, Krzakowski M, Ziolo G, Olechnowicz H, Koubkova L et al. Cisplatin-based three drugs combination (NIP) as induction and adjuvant treatment in locally advanced non-small cell lung cancer: fi nal results. J Th orac Oncol 2008; 3: 152-7.
Liao Y, Lu X, Lu C, Li G, Jin Y, Tang H. Selection of agents for prevention of cisplatin-induced hepatotoxicity. Pharmacol Res 2008; 57: 125-31.
Jiang M, Dong Z. Regulation and pathological role of p53 in cisplatin nephrotoxicity. J Pharmacol Exp Th er 2008; 327: 300- 7.
Cayir K, Karadeniz A, Yildirim A, Kalkan Y, Karakoc A, Keles M et al. Protective eff ect of L-carnitine against cisplatin- induced liver and kidney oxidant injury in rats. Cent Eur J Med 2009; 4: 184-91.
Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specifi cities. J Lipid Res 2005; 46: 1239-47.
Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol effl ux, when present in HDL than in lipoprotein- defi cient serum: relevance to diabetes. Atherosclerosis 2006; 187: 74-81.
Selek Ş, Alp R, İlhan Alp S, Taşkin A. Relationship between PON1 phenotype and headache duration in migraine patients. Turk J Med Sci 2011; 41: 177-184.
Yıldırım A, Aslan Ş, Ocak T, Yıldırım S, Kara F, Şahin YN. Serum paraoxonase/arylesterase activities and malondialdehyde levels in trauma patients. EAJM 2007; 39: 85-8.
Toker A, Kadı M, Yıldırım AK, Aksoy H, Akçay F. Serum lipid profi le paraoxonase and arylesterase activities in psoriasis. Cell Biochem Funct 2009; 27: 176-80.
Demircioğlu RI, Usta B, Sert H, Muslu B, Gözdemir M. Taurine is protective against oxidative stress during cold ischemia in the rat kidney. Turk J Med Sci 2011; 41: 843-849.
Al-Majed AA. Carnitine defi ciency provokes cisplatin-induced hepatotoxicity in rats. Basic Clin Pharmacol Toxicol 2007; 100: 145-50.
Zamami Y, Takatori S, Goda M, Koyama T, Iwatani Y, Jin X et al. Royal jelly ameliorates insulin resistance in fructose- drinking rats. Biol Pharm Bull 2008; 31: 2103-7.
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248- 54.
Beltowski J, Jamroz-Wisniewska A, Borkowska E, Wojcicka G. Diff erential eff ect of antioxidant treatment on plasma and tissue paraoxonase activity in hyperleptinemic rats. Pharmacol Res 2005; 51: 523-32.
Eckerson HW, Wyte CM, La Du BN. Th e human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-38.
Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Pérez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 2007; 7: 3-18.
Kart A, Cigremis Y, Karaman M, Ozen H. Caff eic acid phenethyl ester (CAPE) ameliorates cisplatin-induced hepatotoxicity in rabbit. Exp Toxicol Pathol 2010; 62: 45-52.
Şanlı A, Aydın S, Sarısoy ZA, Paksoy M, Ayduran E, Erdivanli ÖÇ. Th e protective eff ect of dexamethasone and lactate against cisplatin-induced ototoxicity. Turk J Med Sci 2011; 41: 467-74.
Gonzalvo MC, Gil F, Hernandez AF, Rodrigo L, Villanueva E, Pla A. Human liver paraoxonase (PON1): subcellular distribution and characterization. J Biochem Mol Toxicol 1998; 12: 61-9.
Ferré N, Camps J, Prats E, Vilella E, Paul A, Figuera L et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002; 48: 261-8.
Camuzcuoğlu H, Toy H, Vural M, Camuzcuoğlu A, Taşkın A, Çelik H. Serum paraoxonase and arylesterase activities in iron defi ciency anemia during pregnancy. Turk J Med Sci 2011; 41: 185-191.
Goswami B, Tayal D, Gupta N, Mallika V. Paraoxonase: a multifaceted biomolecule. Clin Chim Acta 2009; 410: 1-12.
Hazar A, Dilmeç F, Göz M, Koçarslan A, Aydın MS, Demirkol AH. Th e paraoxonase 1 (PON1) gene polymorphisms in coronary artery disease in the southeastern Turkish population. Turk J Med Sci 2011; 41: 895-902.
Trudel K, Sinnett D, James RW, Delvin E, Amre D, Seidman E, et al. Iron-ascorbic acid-induced oxidant stress and its quenching by paraoxonase 1 in HDL and the liver: comparison between humans and rats. J Cell Biochem 2005; 96: 404-11.
Santos NA, Bezerra CS, Martins NM, Curti C, Bianchi ML, Santos AC. Hydroxyl radical scavenger ameliorates cisplatin- induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Cancer Chemother Pharmacol 2008; 61: 145-55.
Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009; 61: 223-42.
Sadzuka Y, Shoji T, Takino Y. Eff ect of cisplatin on the activities of enzymes which protect against lipid peroxidation. Biochem Pharmacol 1992; 43: 1872-5.
Zhang JG, Lindup WE. Role of mitochondria in cisplatin- induced oxidative damage exhibited by rat renal cortical slices. Biochem Pharmacol 1993; 45: 2215-22.
Kishimoto S, Miyazawa K, Terakawa Y, Ashikari H, Ohtani A, Fukushima S et al. Cytotoxicity of cis-[((1R,2R)-1,2- cyclohexanediamine-N,N’)bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line. Jpn J Cancer Res 2000; 91: 1326-32.
Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin- induced cell death always produced by apoptosis? Mol Pharmacol 2001; 59: 657-63.
Yüce A, Ateşşahin A, Ceribaşi AO, Aksakal M. Ellagic acid prevents cisplatin-induced oxidative stress in liver and heart tissue of rats. Basic Clin Pharmacol Toxicol 2007; 101: 345-9.